Application for clinical trial of corynet for injection of Xiangxue pharmaceutical 1.1 new drug was accepted
-
Last Update: 2015-01-01
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Xiangxue pharmaceutical announced in the evening of December 31, 2014 that the company's application for clinical trials of ketlani for injection was accepted by Guangdong food and drug administration Cotranine for injection is the first new small interfering nucleic acid drug in China, which uses RNA interference (RNAi) technology The drug has not been listed and sold at home and abroad If the above products can be approved and listed, the company will increase its product line in the field of small interference nucleic acid drug synthesis, which is conducive to enhancing the product competitiveness of the company.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
